Stephanie Tsai, MD
Hematology · Maywood, ILNPI 1013144260
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $115,494 of the $160,440 with a category attached, or 72.0%. 12 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 29.8% of the total. 2025 is the largest year on record at $42,151, 4.1 times the $10,257 reported in 2019. Among hematology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 144 payments — averaging $1114.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$48K
- E.r. Squibb & Sons, L.L.C.$40K
- Gamida Cell Inc.$34K
- Sanofi-aventis U.S. LLC$25K
- Bristol Myers Squibb$6K
- Servier Pharmaceuticals LLC$6K
- plus $955 from 6 others
Across 544 payments — averaging $1114.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Macrogenics, Inc.$336K
- Gamida Cell Inc.$173K
- E.r. Squibb & Sons, L.L.C.$27K
- Celularity Inc.$26K
- Sumitomo Pharma America, Inc.$23K
- Incyte Corporation$10K
- plus $12K from 2 others
What the payments were for
- Consulting fees$22,10814%
- Speaking & faculty fees$115,49472%
- Travel & lodging$18,49912%
- Food & beverage$4,3393%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 52 | $47,832 |
| E.r. Squibb & Sons, L.L.C. | 29 | $40,293 |
| Gamida Cell Inc. | 20 | $33,614 |
| Sanofi-aventis U.S. LLC | 19 | $25,387 |
| Bristol Myers Squibb | 7 | $6,446 |
| Servier Pharmaceuticals LLC | 8 | $5,914 |
| AbbVie | 1 | $300 |
| Sanofi | 3 | $255 |
| Novartis | 2 | $204 |
| Syndax Pharmaceuticals, Inc. | 1 | $100 |
| Gilead | 1 | $50 |
| Incyte Corporation | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$160,440 in reported general payments places this provider in the 90th percentile of 49 hematology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 102 | $1,433,323 |
| RezurockBelumosudil Mesylate | 32 | $676,462 |
| BosulifBosutinib | 36 | $658,292 |
| RevlimidLenalidomide | 33 | $590,850 |
| ImbruvicaIbrutinib | 38 | $578,696 |
| Lenalidomide | 28 | $487,885 |
| IdhifaEnasidenib Mesylate | 14 | $423,943 |
| TibsovoIvosidenib | 11 | $334,951 |
| OnuregAzacitidine | 12 | $311,677 |
| PomalystPomalidomide | 11 | $250,049 |
| VenclextaVenetoclax | 45 | $199,517 |
| CalquenceAcalabrutinib Maleate | 12 | $184,229 |
| PromactaEltrombopag Olamine | 12 | $126,180 |
| Imatinib Mesylate | 45 | $5,252 |
| ValacyclovirValacyclovir Hcl | 39 | $2,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $47 | $1,433,323102 claims |
| Bristol Myers SquibbRevlimid, Idhifa | $6,446 | $1,014,79347 claims |
| Sanofi-aventis U.S. LLCRezurock | $25,387 | $676,46232 claims |
| E.r. Squibb & Sons, L.L.C.Onureg, Pomalyst | $40,293 | $561,72623 claims |
| Servier Pharmaceuticals LLCTibsovo | $5,914 | $334,95111 claims |
| AbbVieVenclexta | $300 | $199,51745 claims |
| NovartisPromacta | $204 | $126,18012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 49 hematology providers in Illinois.
Other hematology in Maywood
- Estefania Gauto-MariottiMaywood$3K
- Angela AiMaywood$910
- Samreen FathimaMaywood$29
- Yogesh JethavaPark Ridge$560K
- David GrinblattEvanston$196K
- Jayesh MehtaChicago$183K
- Celalettin UstunChicago$153K
- Kunal DesaiChicago$150K
- John QuigleyChicago$132K
- Parameswa VenugopalChicago$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.